JP7536025B2 - 免疫調節性ポリヌクレオチドコンジュゲートと使用方法 - Google Patents

免疫調節性ポリヌクレオチドコンジュゲートと使用方法 Download PDF

Info

Publication number
JP7536025B2
JP7536025B2 JP2021546200A JP2021546200A JP7536025B2 JP 7536025 B2 JP7536025 B2 JP 7536025B2 JP 2021546200 A JP2021546200 A JP 2021546200A JP 2021546200 A JP2021546200 A JP 2021546200A JP 7536025 B2 JP7536025 B2 JP 7536025B2
Authority
JP
Japan
Prior art keywords
seq
group
sequence
optionally substituted
domain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021546200A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022508825A (ja
JP2022508825A5 (https=
Inventor
ジャウメ ポンス，
ホン アイ． ワン，
カート ダブリュー． ブラッドショー，
バン ジャネット シム，
トレーシー チア－チェン クオ，
Original Assignee
タラック セラピューティクス，インク．
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by タラック セラピューティクス，インク． filed Critical タラック セラピューティクス，インク．
Publication of JP2022508825A publication Critical patent/JP2022508825A/ja
Publication of JP2022508825A5 publication Critical patent/JP2022508825A5/ja
Application granted granted Critical
Publication of JP7536025B2 publication Critical patent/JP7536025B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6807—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug or compound being a sugar, nucleoside, nucleotide, nucleic acid, e.g. RNA antisense
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
JP2021546200A 2018-10-17 2019-10-16 免疫調節性ポリヌクレオチドコンジュゲートと使用方法 Active JP7536025B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862747070P 2018-10-17 2018-10-17
US62/747,070 2018-10-17
US201862747611P 2018-10-18 2018-10-18
US62/747,611 2018-10-18
PCT/US2019/056619 WO2020081744A1 (en) 2018-10-17 2019-10-16 Immunomodulating polynucleotide conjugates and methods of use

Publications (3)

Publication Number Publication Date
JP2022508825A JP2022508825A (ja) 2022-01-19
JP2022508825A5 JP2022508825A5 (https=) 2022-10-21
JP7536025B2 true JP7536025B2 (ja) 2024-08-19

Family

ID=70284225

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021546200A Active JP7536025B2 (ja) 2018-10-17 2019-10-16 免疫調節性ポリヌクレオチドコンジュゲートと使用方法

Country Status (12)

Country Link
US (1) US20220096649A1 (https=)
EP (1) EP3866858A4 (https=)
JP (1) JP7536025B2 (https=)
KR (1) KR20210102204A (https=)
CN (1) CN113660955A (https=)
AU (1) AU2019360216A1 (https=)
BR (1) BR112021007294A2 (https=)
CA (1) CA3116880A1 (https=)
IL (1) IL282282B2 (https=)
MX (1) MX2021004365A (https=)
SG (1) SG11202103805SA (https=)
WO (1) WO2020081744A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2019012295A (es) 2017-04-14 2020-02-07 Tollnine Inc Polinucleotidos inmunomoduladores, conjugados de anticuerpos de los mismos y metodos para su uso.
CA3169523A1 (en) 2020-02-28 2021-09-02 Jaume Pons Transglutaminase-mediated conjugation
KR20240083868A (ko) * 2021-08-20 2024-06-12 탈락 테라퓨틱스, 인크. 넥틴-4 항체 및 접합체
MX2024002407A (es) * 2021-08-25 2024-05-15 Tallac Therapeutics Inc Anticuerpos y conjugados sirp-alfa.
WO2023081934A1 (en) * 2021-11-08 2023-05-11 The University Of Chicago Methods and compositions for pkc-delta inhibition and cancer immunotherapy
KR20250039518A (ko) * 2022-05-18 2025-03-20 탈락 테라퓨틱스, 인크. 항-cd22 항체 올리고뉴클레오타이드 접합체를 사용하여 암을 치료하는 방법
WO2025157804A1 (en) * 2024-01-24 2025-07-31 F. Hoffmann-La Roche Ag Linkers for site-specific protein conjugation

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017143171A1 (en) 2016-02-19 2017-08-24 Genisphere Llc Nucleic acid carriers and therapeutic methods of use
WO2018057669A1 (en) 2016-09-21 2018-03-29 Alexo Therapeutics Inc. Antibodies against signal-regulatory protein alpha and methods of use

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3066105A4 (en) * 2013-11-06 2017-10-11 Solstice Biologics, Ltd. Polynucleotide constructs having disulfide groups
CA2950960A1 (en) * 2014-06-06 2015-12-10 Solstice Biologics, Ltd. Polynucleotide constructs having bioreversible and non-bioreversible groups
US20180134802A1 (en) * 2016-01-08 2018-05-17 The University Of North Carolina At Charlotte Compositions comprising chimeric antigen receptors, t cells comprising the same, and methods of using the same

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017143171A1 (en) 2016-02-19 2017-08-24 Genisphere Llc Nucleic acid carriers and therapeutic methods of use
WO2018057669A1 (en) 2016-09-21 2018-03-29 Alexo Therapeutics Inc. Antibodies against signal-regulatory protein alpha and methods of use

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
KREUTZ, M. et al.，PLoS one，2012年，Vol. 7，No. 7，Article:e40208，pp.1-12.

Also Published As

Publication number Publication date
CN113660955A (zh) 2021-11-16
AU2019360216A1 (en) 2021-05-13
JP2022508825A (ja) 2022-01-19
EP3866858A4 (en) 2022-10-26
MX2021004365A (es) 2021-07-06
KR20210102204A (ko) 2021-08-19
IL282282B1 (en) 2025-03-01
SG11202103805SA (en) 2021-05-28
US20220096649A1 (en) 2022-03-31
IL282282B2 (en) 2025-07-01
CA3116880A1 (en) 2020-04-23
EP3866858A1 (en) 2021-08-25
WO2020081744A1 (en) 2020-04-23
IL282282A (en) 2021-05-31
BR112021007294A2 (pt) 2021-07-27

Similar Documents

Publication Publication Date Title
JP7536025B2 (ja) 免疫調節性ポリヌクレオチドコンジュゲートと使用方法
US12527838B2 (en) Combination therapies comprising an agent that blocks the interaction between CD47 and SIRPα for treating gastric or gastroesphageal junction cancel
ES3030503T3 (en) Chimeric antigen receptor effector cell switches with humanized targeting moieties and/or optimized chimeric antigen receptor interacting domains and uses thereof
CN108350082A (zh) Pd-l1抗体及其用途
US20240043490A1 (en) Targeted cytokine construct for engineered cell therapy
WO2019195408A1 (en) Antibody variable domains targeting dll3, and use thereof
TW202003581A (zh) 對cd3具特異性之抗體及其用途
JP7682104B2 (ja) 非小細胞肺がんを処置するための方法および組成物
JP2024537772A (ja) Ｂａｆｆ－ｒを標的化する抗体及びその使用
JP2022537269A (ja) Ｍｕｃ１６およびｃｄ３に結合する二重特異性抗原結合分子の４－１ｂｂ共刺激と組み合わせての使用
TW202003044A (zh) 可釋放之抗體結合物
US20250228955A1 (en) Platform technology for bispecific antigenbinding proteins
US20250161481A1 (en) Targeted lnp delivery
WO2025179294A2 (en) Immune engineering amplification
TWI913247B (zh) 轉穀胺醯胺酶介導之結合
WO2024206329A1 (en) Nucleic acid molecules encoding bi-specific secreted engagers and uses thereof
EP4680645A1 (en) Fusion protein and uses thereof
HK40025067B (zh) 抗pd-l1抗体及其用途
HK1259426B (zh) Pd-l1抗体及其用途

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221013

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20221013

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20231121

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240213

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240422

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20240723

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20240806

R150 Certificate of patent or registration of utility model

Ref document number: 7536025

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150